2026
conference-abstract
OpenAlex
Tam Binh V. Bui, D. M. Wolf, R. W. Sayaman, C. Yau et autres
Abstract Introduction The I-SPY2 neoadjuvant platform trial (NCT01042379) evaluates new therapies in high molecular risk breast cancer patients. From 2010-2022, 24 therapies were tested in 2117 patients. One-third of these patients had HER2-negative tumors with low expression of immune genes and no …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Jean-Philippe Coppé, Bettina Kritzer, Yeonjoo C Hwang, Bavani Subramaniam et autres
Abstract Diffuse midline glioma (DMG) accounts for 10% of pediatric cancers of the central nervous system. Despite extensive research and clinical trials, there is still no effective treatment for children diagnosed with DMG. The prognosis remains poor with a median survival time …
us, ch
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Robert E. Doherty, Kelsey Wink, Kallen Schwark, Sunjong Ji et autres
Abstract Diffuse midline gliomas (DMGs) are lethal pediatric high-grade brain tumors with a prognosis of less than two years from diagnosis. A subgroup of DMGs harbor alterations in epidermal growth factor receptor (EGFR), including wildtype amplification (WT) and mutations in the extracellular …
us, ch, de
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Kallen Schwark, Madeline Miclea, Tirth Patel, Seongbae Kong et autres
Abstract PDGFRA is a frequently altered gene in pHGG, driving aggressive behavior and worse prognoses. Avapritinib, a potent CNS-penetrant PDGFRA inhibitor, has shown promise in vitro, in vivo, and in pHGG patients. Given the failure of single-agent trials in targeting PDGFRA-altered HGG, …
us, ch, de, at
(code pays fourni par la source)